A major objective of the Pharmaceutical Research Laboratory is to discover pharmaceuticals that promise to be beneficial to society, and realize the market release of proprietary drugs. UBE carries out new drug research on its own as well as jointly with pharmaceutical companies under a collaborative framework. In both cases, the laboratory sets specific research goals to rapidly develop candidate compounds and realize results, in order to expand the pipeline through the successive development of new drugs.
In independent research, UBE is aiming to achieve commercialization through licensing our achievements to major pharmaceutical companies in and outside of Japan. Collaborative research is followed by joint development with partner companies, aiming for marketing approval and commercialization.
In Japan, UBE has successfully obtained approval for and brought to market the antiallergic agent Talion® and the antihypertensive agent Calblock®. The antiplatelet agent Effient®, which UBE co-developed with Daiichi Sankyo Co., Ltd., has been launched worldwide by Daiichi Sankyo and Eli Lilly and Company. UBE actively pursues independent research, efficiently advancing new drug research to identify candidate compounds based upon the efforts of the Medicinal Chemistry Group, Project Management Group, Pharmacology Group and Drug Discovery DMPK Group.